Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Use of Biological Surfactant as Anti-flammatory Agent and Tissue Preservative Solution
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Cancer immunotherapy using dendritic cells, and iii) Camel recombinant antibodies for FoxP3, Mucl & CEA. ...
Contact Yong U Kim
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
Efficacy of Biological Surfactant , Safety of Biological Surfactant, Treatment of immune-mediated diseases, Use of tissue preservative solution

Active ingredients as anti-inflammatory agents


Anti-Sepsis agents developed by SHAPERON, comprise biological surfactant as active ingredients for intravenous injection.


Biological surfactant used to anti-Sepsis agents, is selected from a group consisting of cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid, dehydrocholic acid, a conjugate compound of these acids with glycine or taurine and pharmaceutically acceptable salts thereof.


Specific experimental results below, are related to CCA(conjuaged cholic acids) including GC(sodium glycocholic acid), TCD(sodium taurchenodeoxycholic acid) and TD(sodium taurodeoxycholic acid) as biological surfactiant,


Characteristics of Biological surfactant as anti-Sepsis agents


As Biological surfactant is theraputic agents targating LPS, it inhibits binding of LPS with cells and NF- κ B activation, one of the most crucial signaling pathways in proinflammatory responses by LPS.


 

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE